Neoplasms

All Conditions

Rare Diseases

Hemangiosarcoma

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neoplasms, Vascular Tissue

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Talimogene laherparepvec

Participants will undergo intralesional injections of up to 4 cc of 10\^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10\^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.

Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.

T-VEC

John Mullinax, MD,

This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

A Phase II Study of Talimogene Laherparepvec (T-VEC) in the Treatment of Locally Advanced Cutaneous Angiosarcoma

Overall response rate is defined as the proportion of patients who demonstrate complete or partial responses in injected lesions per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria appropriate for cutaneous neoplasms (ORR=complete response + partial response).

Response duration will be measured from the time of initial partial response or complete response until documented progression.

The duration of overall response is measured from the time measurement criteria are met for Complete Response or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

Progression-free survival is defined as the period of time from the first injection to progression of disease or appearance of new cutaneous angiosarcomas that were not present at the time of study entry

Complete response rate is defined as the proportion of participants that have lesions with complete clinical regression

Measuring the rate of participants requiring surgical resection of T-VEC treated lesions

Measuring the degree of immune infiltration in surgically resected T-VEC treated tumors

H. Lee Moffitt Cancer Center and Research Institute

No anticipated or unanticipated serious adverse events happened to participants on trial.

Participants will undergo intralesional injections of up to 4 cc of 10\^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10\^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.

T-VEC: Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.

Spots Global Cancer Trial Database for Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial